Sana Biotechnology (SANA) Share-based Compensation (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Share-based Compensation data on file, last reported at $33.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 377.74% year-over-year to $33.5 million; the trailing twelve-month figure through Mar 2026 stood at $33.5 million (down 5.79% YoY), and the FY2025 full-year result was $25.5 million, down 32.42% from the prior year.
• Share-based Compensation climbed to $33.5 million in Q1 2026, from $6.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $33.5 million in Q1 2026 to a low of $3.4 million in Q1 2022.
• A 5-year average of $10.3 million and a median of $9.1 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation sank 41.75% in 2025 and soared 377.74% in 2026, its largest moves.
• Tracing SANA's Share-based Compensation over 5 years: stood at $10.6 million in 2022, then fell by 25.12% to $7.9 million in 2023, then retreated by 18.85% to $6.4 million in 2024, then fell by 1.54% to $6.3 million in 2025, then jumped by 429.38% to $33.5 million in 2026.
• Business Quant data shows SANA's Share-based Compensation at $33.5 million in Q1 2026, $6.3 million in Q4 2025, and $13.7 million in Q3 2025.